OUR TEAM

Andrew E. Morrell

Counsel

Madison, NJ
One Giralda Farms
Madison, NJ 07940
P 973.966.3246 F 973.966.3250
 P 973.966.3246 F 973.966.3250
EMAIL   |   DOWNLOAD VCARD

Experience

Andrew represents clients in intellectual property matters focused in the pharmaceutical, chemical and biotechnology industries. His practice is varied and often allows him to utilize the technical training he received while earning his Ph.D. in Medicinal Chemistry & Molecular Pharmacology for research on the synthesis and biological evaluation of small molecule therapeutics.

Andrew regularly litigates matters brought under the Hatch-Waxman Act and counsels clients as they prepare their Abbreviated New Drug Applications (ANDAs). He also represents both patent owners and petitioners in administrative proceedings before the Patent Trial and Appeal Board (PTAB). In addition, he helps clients obtain patents, analyzes third-party patents, conducts due diligence studies, and prepares opinions on patent-related issues.

Prior to Windels Marx, Andrew practiced at a boutique IP law firm over the course of a decade. From 2017 to 2019, he served as a judicial law clerk for the Honorable Pauline Newman of the U.S. Court of Appeals for the Federal Circuit - the appellate court hearing all patent appeals coming out of district courts, the United States Patent and Trademark Office, and the ITC. He also was in-house at a global healthcare company, where he focused on global IP counsel.

Representative Matters

  • Bristol-Myers Squibb Co. v. Lupin Inc., Case No. 3:20-cv-07810 (2021) - Represented Lupin in Hatch-Waxman litigation in the District of New Jersey concerning patents related to dasatinib (the active ingredient in BMS's Sprycel® product). Achieved a favorable disposition for the client prior to claim construction briefing.

Publications

Andrew has contributed to more than 23 peer-reviewed scientific articles, including:

  • N. Nenortas, M. Cinelli, A. Morrell, M. Cushman, & T. Shapiro, “Activity of Aromathecins Against African Trypanosomes,” Antimicrob. Agents Chemother. 2018, 62, e00786–18.
  • M. Conda-Sheridan, P. V. Narasimha Reddy, A. Morrell, B. T. Cobb, C. Marchand, K. Agama, A. Chergui, A. Renaud, A. G. Stephen, L. K. Bindu, Y. Pommier, & M. Cushman, “Synthesis and Biological Evaluation of Indenoisoquinolines That Inhibit Both Tyrosyl-DNA Phosphodiesterase I (Tdp1) and Topoisomerase I (Top1),” J. Med. Chem. 2013, 56, 182-200.
  • L. Chen, M. Conda-Sheridan, P. V. N. Reddy, A. Morrell, E.-J. Park, T. P. Kondratyuk, J. M. Pezzuto, R. B. van Breemen, & M. Cushman, “Identification, Synthesis, and Biological Evaluation of the Metabolites of 3-Amino-6-(3'-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11-dione (AM6-36), a Promising Rexinoid Lead Compound for the Development of Cancer Chemotherapeutic and Chemopreventive Agents,” J. Med. Chem. 2012, 55, 5965–81.
  • E. Kiselev, S. DeGuire, A. Morrell, K. Agama, T. S. Dexheimer, Y. Pommier, & M. Cushman, “7-Azaindenoisoquinolines as Topoisomerase I Inhibitors and Potential Anticancer Agents,” J. Med. Chem. 2011, 54, 6106–16.
  • M. A. Cinelli, A. E. Morrell, T. S. Dexheimer, K. Agama, S. Agrawal, Y. Pommier, & M. Cushman, “The Structure–activity Relationships of A-Ring-substituted Aromathecin Topoisomerase I Inhibitors Strongly Support a Camptothecin-like Binding Mode,” Bioorg. Med. Chem. 2010, 18, 5535–52.
  • R. P. Bakshi, D. Sang, A. Morrell, M. Cushman, & T. A. Shapiro, “Activity of Indenoisoquinolines against African Trypanosomes,” Antimicrob. Agents Chemother. 2009, 53, 123–28.
  • M. A. Cinelli, A. Morrell, T. S. Dexheimer, E. S. Scher, Y. Pommier, & M. Cushman, “Design, Synthesis, and Biological Evaluation of 14-Substituted Aromathecins as Topoisomerase I Inhibitors,” J. Med. Chem. 2008, 51, 4609–19.
  • A. Morrell, S. Antony, G. Kohlhagen, Y. Pommier, & M. Cushman, “Nitrated Indenoisoquinolines as Topoisomerase I Inhibitors: A Systematic Study and Optimization,” J. Med. Chem. 2007, 50, 4419–30.
  • A. Morrell, M. Placzek, S. Parmley, S. Antony, T. Dexheimer, Y. Pommier & M. Cushman, “Optimization of the Indenone Ring of Indenoisoquinoline Topoisomerase I Inhibitors,” J. Med. Chem. 2007, 50, 4388–404.
  • A. Morrell, S. Antony, G. Kohlhagen, Y. Pommier, & M. Cushman, “A Systematic Study of Nitrated Indenoisoquinolines Reveals a Potent Topoisomerase I Inhibitor,” J. Med. Chem. 2006, 49, 7740–53.
  • A. Morrell, S. Antony, G. Kohlhagen, Y. Pommier & M. Cushman, “Synthesis of Benz[d]indeno[1,2-b]pyran-5,11-diones: Versatile Intermediates for the Design and Synthesis of Topoisomerase I Inhibitors,” Bioorg. Med. Chem. Lett. 2006, 16, 1846–49.
  • A. Morrell, S. Antony, G. Kohlhagen, Y. Pommier, & M. Cushman, “Synthesis of Nitrated Indenoisoquinolines as Topoisomerase I Inhibitors,” Bioorg. Med. Chem. Lett. 2004, 14, 3659–63.

Recognition

  • Best Lawyers: Ones to Watch - Intellectual Property Litigation (2021-2023)

Practices

Education

  • J.D., magna cum laude, George Mason University, 2010
  • Ph.D., Medicinal Chemistry & Molecular Pharmacology, Purdue University, 2007
  • B.S., Chemistry & Biology, summa cum laude, King College, 2001

Admissions

  • California
  • District of Columbia
  • United States Court of Appeals for the Federal Circuit
  • United States District Court for the Southern District of California
  • United States Patent and Trademark Office